Navigation Links
Loyola fellow receives Amgen grant to study treatments for older leukemia patients
Date:6/4/2009

MAYWOOD, Il. -- Dr. Aileen Go of Loyola University Health System, who is studying treatment options for older leukemia and lymphoma patients, has won a prestigious Amgen Foundation Fellowship grant.

Go, a second-year fellow in hematology/oncology, will work with Dr. Patrick Stiff, director of Loyola's Cardinal Bernardin Cancer Center. Stiff and Go are studying the use of umbilical cord blood transplants grown from cord blood cells outside the body. The transplants are intended for patients ages 55 to 75, who previously have been excluded from such treatments.

Patients will receive high-dose chemotherapy, which, in addition to killing cancer cells also destroys the patients' immune system cells. To build a new immune system, patients receive transplanted stem cells, which develop into new immune system cells.

Older patients generally cannot tolerate high-dose chemotherapy. Go and Stiff will study a reduced-intensity chemotherapy regimen, as well as a method for boosting the number of stem cells.

The stem cells will come from donated umbilical cord blood. A newborn's cord blood does not contain enough stem cells for most adult patients. So the cord blood will be sent to a lab that will grow more stem cells prior to the transplant.

The Amgen Foundation provides grants for such purposes as advancing science education and improving the quality of care and access for patients. The one-year award that Go received is given to medical researchers who are beginning to pursue academic careers.

"These are very competitive, with the majority of the awards going to MDs and PhDs who submit truly amazing projects for funding," Stiff said.

Dr. Paul Whelton, president and CEO of Loyola University Health System, added that Loyola is "a home for the next generation of leaders -- those who will make a difference in reducing the burden of illness in society."


'/>"/>

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System
Source:Eurekalert

Page: 1

Related medicine news :

1. Nine Journalists Named as 2009 Kaiser Media Fellows
2. MHA Clinical Director Kimberly Binaso, Pharm.D. Awarded 2009 ASHP Fellow
3. Eye association inducts inaugural class of Fellows
4. Hahnemann University Hospital Granted Surgical Fellowship Training Program for Pelvic Floor Disorders
5. AAPS and FDA announce appointment of research fellow
6. ARVO announces inaugural class of Fellows
7. Actress and Mom Alison Sweeney Teams Up With the American Pharmacists Association to Help Fellow Allergy Sufferers Find Relief This Spring
8. National Medical Fellowships Honors Three Outstanding Healthcare Leaders at Annual Awards Gala
9. American Lung Association Salutes Fellow Advocates in the Fight Against Tuberculosis on 2009 World TB Day
10. Hawaii's Most Experienced and Only Fellowship-Trained Weight Loss Surgeon Now Coming to Hilo
11. Lincoln Park Zoo researcher awarded prestigious conservation biology fellowship
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)NEW ORLEANS, Dec. 5 Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology int
(Date:12/5/2009)The MAMA campaign is a collaborative effort by the National Association of Certified Professional Midwives (NACPM), Midwives Alliance of North America (MANA), Citizens for Midwifery (CfM), Internation
(Date:12/4/2009)SAN FRANCISCO, Dec. 4 Medithrive, Inc. has won the Patient,s Choice Award as the favorite dispensary in the SF Bay Area by popular vote conducted by the online website, www.weedmaps.com. Despite on
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)STANFORD, Calif. A new study shows that muscle cells grown in the lab can restore an intestine,s ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat pa
Breaking Medicine News(10 mins):Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 4Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4
...vide Market-Leading Dental Tools and Services to ...NAPOLIS, April 29 WellPoint, Inc. (NYSE:,WLP), th...announced the,acquisition of DeCare Dental, one of...roup customers. The acquisition of,DeCare enhances...
...ril 29 Hundreds of,bicyclists are expected to par...e-day fundraising ride starting in Newton, Massach...is July 18-20. The event and its,participants rais...mmer, the Trek is distributing cowbells in the,com...
... LAUNCHES, FREDERICK, Md., April 29 BioElectroni...ew website, http://www.actipatch.it ,is now selli...SS Medical,(Tecnica Scientifica Service), designed...uartered in Torino, Italy. Over,10,000 ActiPatch u...
...pril 29 In conjunction,with DURECT Corporation,s ...lts press release, you are invited to listen to th... the Internet on Wednesday, May 7th, 2008,at 4:30 ... by accessing,DURECT,s homepage at http://www.dur...
...50 had agreement on standard outcomes, review find...- Few studies consider the appropriate measurement...hildren, say University of Liverpool researchers w...ldren in the process to select which measurements ...
...may now be predicted more realistically according ...rnal of Clinical Endocrinology & Metabolism (JCEM)...MH) levels are related to the onset of menopause a... small follicles present in a womans ovaries. This...
Other Medicine News:Health News:WellPoint Announces Acquisition of DeCare Dental 2Health News:WellPoint Announces Acquisition of DeCare Dental 3Health News:WellPoint Announces Acquisition of DeCare Dental 4Health News:WellPoint Announces Acquisition of DeCare Dental 5Health News:More Cowbell! To end ALS, Riders of the Tri-State Trek Cycle 270 Miles - Making Noise and Raising Money! 2Health News:More Cowbell! To end ALS, Riders of the Tri-State Trek Cycle 270 Miles - Making Noise and Raising Money! 3Health News:BioElectronics Corporation Announces New Website for Italian Market 2Health News:BioElectronics Corporation Announces New Website for Italian Market 3Health News:Measurements Poor for Assessing Clinical Trials With Children 2
(Date:12/3/2009)DOYLESTOWN, Pa., Dec. 3 Ted Karkus, Chairman and CEO of The Quigley Corporation, (Nasdaq: QGLY ) www.quigleyco.com announced today that the Company has completed its evaluation of its opportunitie
(Date:12/3/2009)WILMINGTON, Del., Dec. 3 ParagonRx, a Delaware-based company specializing in pharmaceutical risk management and optimal medication use, will host a free webinar on Wednesday, Dec. 9, on the FDA,s dra
(Date:12/3/2009)DURHAM, N.C., Dec. 3 In response to the increasingly critical role of healthcare information technologies in the evolving healthcare delivery system, Duke Medicine has created the Duke Center for Hea
Breaking Medicine Technology:Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3Duke Medicine to Train Healthcare Professionals in Health Informatics 2Duke Medicine to Train Healthcare Professionals in Health Informatics 3New test for safer biomedical research results 53248 1New test for safer biomedical research results 53248 2Sun exposure may trigger certain autoimmune diseases in women 53245 1Sun exposure may trigger certain autoimmune diseases in women 53245 2Got zinc 3F New zinc research suggests novel therapeutic targets 9433 1Got zinc 3F New zinc research suggests novel therapeutic targets 9433 2
...tion at 24 Months, SAN DIEGO, Dec. 12 Ceregene, ... a Phase 1 clinical trial of CERE-120 in 12,patien...s gene therapy to,deliver the neural growth factor...that occurs in the brains of Parkinson,s disease,p... 24 months post,treatment, suggest a sustained red...
... Inc., a,biotechnology company developing orally a...at the Company has initiated a multi-dose trial wi...ent for smallpox infection. This,trial will study ...the drug,given to healthy volunteers., "The high ...ase I trial,has validated the utility of the compa...
Other Medicine Technology:Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's Disease 2Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's Disease 3Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's Disease 4Chimerix Initiates a Multi-dose Clinical Trial of the Company's Lead Compound, CMX001, for the Treatment for Smallpox Infection 2
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
Medicine Products: